Abstract
Background COVID-19, caused by the novel SARS-CoV-2 is the worst catastrophe in this century that affected more than 800 million people and caused more than 7 million deaths. During the pandemic, the burden of COVID-19 increased significantly, posing a threat to public health infrastructure, testing protocols, national healthcare capacity, and disease control measures. To assess the impacts of the Nigerian Health Systems on COVID-19 fatalities, the researchers evaluated the association between healthcare system capability and mortality rate of COVID-19 patients through adjustments for healthcare spending as a proportion of the GDP, population density, and the proportion of the population that are 65 years and above across the 36 States and Abuja, FCT.
Methods The study utilized secondary data abstracted from the World Bank records, Worldometer, and Post-Pandemic Health Financing by the States in Nigeria (2020 to 2022). It used data from the 36 States of the country and the FCT, Abuja. The dependent variable was COVID-19 case fatality (Case Fatality Rate across the study areas), the predictor variable was Healthcare Capacity Index (aggregate of number of doctors/nurses/midwives/hospital bed space per 1,000 population categorized into low, middle, and high Healthcare Capacity index), and the covariates were population density, health expenditure as a percentage of GDP, and the proportion of the population that are 65 years and above. A negative binomial regression model was used to assess the predictors of case fatality after adjusting for other covariates at an alpha of <0.05 and 95% confidence interval.
Results Almost half of the States in Nigeria were in the middle Healthcare Capacity Index 16 (43.2%) with only 7 (18.9%) in the high Healthcare Capacity Index (HCI). The regression analysis shows that HCI was a predictor of COVID-19 case fatality as the States with high HCI compared with low HCI were 9.4 times more likely to have lower COVID-19 case fatalities (AOR=0.106, p=0.063, 95% CI[0.010-1.131]), and those with middle HCI compared with low were 6.4 times more likely to have lower COVID-19 case fatality (aOR=0.156, p=0.006, 95% CI [0.041-0.593]). Although States with a higher proportion of the population that were 65 years and above were about 2 times more likely to have higher COVID-19 case fatality (aOR 1.99, p=0.154, 95% CI [0.771-5.172]), this was not statistically significant due to the small sample size (37 States)
Conclusion The research further buttressed the pivotal role that effective multidimensional healthcare capacity is a pertinent strategy to mitigate future case fatalities from Public Health Events of International Concerns (PHEICs).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study requires no ethical approval. The study utilized secondary data abstracted from the World Bank records, Worldometer, and Post-Pandemic Health Financing by the States in Nigeria (2020 to 2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
World Bank records (https://data.worldbank.org/indicator/SH.MED.NUMW.P3?locations=NG), Worldometer (https://www.worldometers.info/), and Post-Pandemic Health Financing by the States in Nigeria 2020 to 2022 (https://cdn.one.org/pdfs/ONE_2022_Nigeria_Budgetary_Health_Report.pdf)
https://cdn.one.org/pdfs/ONE_2022_Nigeria_Budgetary_Health_Report.pdf
https://data.worldbank.org/indicator/SH.MED.NUMW.P3?locations=NG